This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board to approve September 2026 quarterly and half-year results
SHUKRAPHAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts more than Nifty Microcap 250 and 5.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board will meet on 3 November 2026 to approve the company’s unaudited financial results for the quarter and six months ended 30 September 2026, along with the auditor’s limited review report. No financial figures or operating updates are provided yet.
No immediate impact can be assessed because the financial results are still pending. The report may influence investor sentiment when released.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹44.20 Cr against ₹5.88 Cr a year ago, about 8× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.